Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec: First half year 2018/2019: Continued profitable growth for Carl Zeiss Meditec

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/06/2019 | 03:43am EDT
JENA/Germany, 06.05.2019. In the first half of fiscal year 2018/19 Carl Zeiss Meditec generated revenue of €667.2m, representing an increase of 8.7 percent (adjusted for currency effects: +6.8 percent; prior year's revenue: €613.7m). Earnings before interest and taxes (EBIT) increased significantly to €110.4m (prior year: €88.2m). The EBIT margin also increased, to 16.5 percent (prior year: 14.4 percent).

'In the first half of 2018/19, we have continued on our growth path, with a strong contribution from new products and a high level of recurring revenue', comments Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Solid growth in both strategic business units

The Ophthalmic Devices strategic business unit (SBU) increased its revenue by 9.2 percent in the first half of fiscal year 2018/19 (adjusted for currency effects: +7.4 percent), to €490.7m, compared with €449.3m in the same period of the prior year. This revenue increase is mainly attributed to the unchanged high demand for laser vision correction solutions as well as products for cataract surgery.
Revenue in the Microsurgery SBU grew by 7.4 percent (adjusted for currency effects: +5.2 percent), to €176.5m, compared with €164.4m in the same period of the prior year. Sales of neurosurgical visualization systems for the treatment of tumors and vascular diseases remained strong.

Significant growth, particularly in the EMEA region

Revenue in the EMEA1 increased by 10.7 percent (adjusted for currency effects: +11.6 percent), to €213.7m (prior year: €193.0m). Germany, France and Spain all posted strong revenue growth.
At €180.9m (prior year: €181.6; -0.4 percent, adjusted for currency effects: -5.0 percent), revenue in the first half of the current fiscal year in the Americas region was slightly below the prior year's figure. This development is primarily attributable to new product launches in the first half of the 2017/18 fiscal year, which had provided a strong boost to revenue in the same period of the prior year.

The APAC2 also posted a further increase in its revenue, of 14.0 percent (adjusted for currency effects: +12.3 percent) to €272.6m (prior year: €239.1m). Strongest contribution came again from China and South Korea.

The operating result (EBIT) increased significantly and reached €110.4m in the first half of the current fiscal year (prior year: €88.2m). This increase was mainly driven by a favourable development of product mix with a high share of recurring revenue. The EBIT margin increased from 14.4 percent to 16.5 percent. Adjusted for special effects, this represented an increase to 16.8 percent (prior year: 14.7 percent). Earnings went up to €0.65 per share from the €0.63 of the same period in the previous year.

'With the results of the first half of the fiscal year in the books, we are now able to provide a more precise forecast:' says Dr. Ludwin Monz: 'We expect to achieve sales of € 1,350 million - € 1,420 million for the full year. Due to the strong level of the EBIT margin in the first half, we are adjusting our expectations for the current fiscal year 2018/19 and now expect an EBIT margin between 15.0 percent to 17.5 percent (up from previously: 14.0 percent to16.0 percent). The forecast for the mid-term development of the EBIT margin will be reviewed as part of the publication of the financial results for 2018/19, considering the planned strategic investments in research and development.'

Revenue by strategic business unit



























All figures in €m
6 months
2018/19
6 months
2017/18
Change from prior year Change from prior year*
Ophthalmic Devices 490.7 449.3 +9.2% +7.4%
Microsurgery 176.5 164.4 +7.4% +5.2%
Overall group 667.2 613.7 +8.7% +6.8%

*adjusted for currency effects

Revenue by region
































All figures in €m
6 months
2018/19
6 months
2017/18
Change from prior year Change from prior year*
EMEA 213.7 193.0 +10.7% +11.6%
Americas 180.9 181.6 -0.4% -5.0%
APAC 272.6 239.1 +14.0% +12.3%
Overall group 667.2 613.7 +8.7% +6.8%

*adjusted for currency effects

1Europe, Middle East, Africa
2Asia/Pacific

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Fax:
investors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at: www.zeiss.com/med

Number: 0042-2019-ENG OP

Number of Words: 900
Number of Characters: 6956

Disclaimer

Carl Zeiss Meditec AG published this content on 06 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 06 May 2019 07:42:03 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
08/12CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
AQ
08/09EUROPE : Italy leads European shares lower on political uncertainty
RE
08/09GLOBAL MARKETS LIVE : Bayer, Huawei, Airbus, Occidental Petroleum…
08/09CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
EQ
08/02CARL ZEISS MEDITEC AG : Preliminary announcement of the publication of quarterly..
EQ
07/16INFORMATION PURSUANT : Carl Zeiss Meditec is aiming for the upper end of its rev..
PU
07/15CARL ZEISS MEDITEC : is aiming for the upper end of its revenue forecast for the..
EQ
06/19EUROPE : European stocks tread water, all eyes on Fed
RE
06/18A pivotal month of June
06/04A war on all fronts
More news
Financials (EUR)
Sales 2019 1 428 M
EBIT 2019 263 M
Net income 2019 169 M
Finance 2019 663 M
Yield 2019 0,67%
P/E ratio 2019 51,9x
P/E ratio 2020 44,6x
EV / Sales2019 5,73x
EV / Sales2020 5,21x
Capitalization 8 846 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 88,98  €
Last Close Price 98,75  €
Spread / Highest target 1,27%
Spread / Average Target -9,89%
Spread / Lowest Target -44,3%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG44.80%9 796
THERMO FISHER SCIENTIFIC33.00%119 202
DANAHER CORPORATION36.75%101 163
INTUITIVE SURGICAL9.25%60 303
BOSTON SCIENTIFIC CORPORATION18.31%58 240
EDWARDS LIFESCIENCES CORPORATION43.30%45 649